BiotechTube
Home/Pipeline/SIMBs + Immunotherapy

SIMBs + Immunotherapy

Pancreatic Cancer

Pre-clinicalValidated in preclinical studies

Key Facts

Indication
Pancreatic Cancer
Phase
Pre-clinical
Status
Validated in preclinical studies
Company
Advanced Microbubbles

About Advanced Microbubbles

Advanced Microbubbles is addressing the critical challenge of inefficient drug delivery in oncology, where less than 1% of injected drugs typically reach their target. Their core innovation is the creation of stable, large, monodisperse microbubbles that, when combined with ultrasound, can non-invasively open biological barriers to enable precise delivery of various therapeutic agents. The platform has shown promising preclinical results in models of pancreatic cancer, neuroblastoma, and for blood-brain barrier opening, positioning the company to advance a versatile, drug-agnostic delivery technology.

View full company profile

Therapeutic Areas

OncologyCNS Disorders

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b
Electron IORTIntraop MedicalApproved